DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Management of Soil-transmitted Helminthiasis and Strongyloidiasis

Information source: Universidad Nacional de Salta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Helminthiasis; Strongyloides Stercoralis Infection

Intervention: Ivermectin + Albendazole (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Universidad Nacional de Salta

Official(s) and/or principal investigator(s):
Alejandro Krolewiecki, MD, PhD, Principal Investigator, Affiliation: Universidad Nacional de Salta, Instituto de Investigación en Enfermedades Tropicales

Overall contact:
Alejandro Krolewiecki, MD, PhD, Phone: +54-11-45531369, Email: alekrol@hotmail.com


The general purpose of the project is to analyse soil-transmitted helminthiases (STH) in a highly endemic area in northern Argentina with a multidisciplinary approach. The specific objectives are to evaluate the local epidemiology of STH, validate a new diagnostic serology method for S. stercoralis and evaluate the efficacy and safety of a mass drug administration regimen with albendazole and ivermectin.

Clinical Details

Official title: Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluation of local epidemiology of soil-transmitted helminthiases and impact of a mass drug treatment anti-helminthic strategy

Secondary outcome:

Validate serology methods for diagnosis of S. stercoralis infection

Assess the tolerability and safety of the combination of ivermectin and albendazole


Minimum age: 1 Year. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- All persons that are living in the working area at the time of the intervention and

wish to participate in the study. Exclusion Criteria: 1. All persons that live within the study area but do not want to participate in the study. 2. Pregnant women or women who are likely pregnant. 3. Women during the first post-partum week if they are breastfeeding. 4. Children who weigh less than 15 kg. 5. Persons with a history of hypersensitivity or intolerance to ivermectin, albendazole or to the components that make up those drugs.

Locations and Contacts

Alejandro Krolewiecki, MD, PhD, Phone: +54-11-45531369, Email: alekrol@hotmail.com

Instituto de Investigación en Enfermedades Tropicales, Universidad Nacional de Salta, Orán, Salta 4530, Argentina; Recruiting
Additional Information

Starting date: December 2010
Last updated: March 3, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017